Clinical trial
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT04319757
Study timeline
Study start (actual)2020-06-24Date precision: day
Registry last updated2024-12-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Locally Advanced Solid Tumorunresolved
Metastatic Cancerunresolved
Solid Tumorunresolved
HER2-positive Gastric Cancerunresolved
HER2-positive Metastatic Breast Cancerunresolved
Interventions
ACE1702DRUG
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
FludarabineDRUG · verified · RxNorm: fludarabine
Sponsors & collaborators
Acepodia Biotech, Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04319757 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.